Over the last twenty years, Dr. Michael Corrado has established himself as an expert in the pharmaceutical industry. After spending eight years with Merck and eight years with Johnson & Johnson, Dr. Corrado partnered with Howard Solomon to found Advanced Biologics in 1995. He has been intricately involved in the complete development of numerous infectious disease compounds, from pre-clinical work through to marketing application submission. Dr. Corrado has served as Primary Medical Author of six NDAs, five sNDAs, and several expert reports submitted to European regulatory bodies. Included in the impressive list of infectious disease compounds he has worked on are norfloxacin, ofloxacin, levofloxacin, chibroxin, Mefoxin®, Primaxin®, Pneumovax®, Renova®, Ultram®, and an AIDS test kit. Dr. Corrado has numerous publications and presentations to his credit and is a member of the IDSA - FDA Anti-infective Guidelines Committee. He is also a reviewer of anti-microbial agents and chemotherapy for the Archives of Internal Medicine. Dr Corrado received his medical degree from Meharry Medical College of Medicine.

Dr. Crawford worked as a Molecular Biologist at List Biological Laboratories (Campbell, CA). List Biological Labs is a leading manufacturer of biological toxins used for research as well as in industrial and medical applications. Subsequently, Dr. Crawford earned his Ph.D. in glycobiology from the University of California, San Diego in 2004. He trained with Dr. Esko studying the role of glycans in cancer. During his graduate work Dr. Crawford made a number of important discoveries correlating glycan structure and expression with function. Dr. Crawford has played a major role in developing the Zacharon’s drug discovery system.

Dr. Esko’s pioneering approach using mutant cells in his lab at the University of Alabama, Birmingham (1983-1996) and then later using genetically altered mice at the University of California, San Diego has helped elucidate many key functions played by glycans and has lead to over 100 publications, a March of Dimes Basil O’Connor Award (1984-1986) and a 10 year NIH MERIT award in 1999. At UCSD, Dr. Esko’s lab continues to be a leader in the field of glycobiology. He also co-directs the Glycobiology Research and Training Center. Dr. Esko was President of the Society for Glycobiology in 2002-2003.

Dr. Esko recognized the importance of glycans as drug targets early on and served on the Scientific Advisory Board for one of the original glycobiology biotech companies, Glycomed (1990 – 1995). Since then he has had continuous demand for his expertise in glycobiology and has consulted for a number of biotechnology and pharmaceutical companies. Dr. Esko received his Ph.D. from the University of Wisconsin, Madison. Dr. Esko is currently a Professor at the Department of Cellular and Molecular Medicine at University of California at San Diego.

Before entering the field of Glycobiology, Dr Glass was a Senior Scientist at Johnson and Johnson Pharmaceutical Research Institute directing molecular biological projects toward drug-target gene discovery. Dr. Glass recognized the intense competition for novel drug targets and was attracted to Dr. Esko’s lab to study the glycan field where there is an entire class of untapped scientifically verified drug targets. In 1999, Dr Glass moved from the R.W Johnson Pharmaceutical Research Institute (RWJ-PRI) in La Jolla to the University of California, San Diego (UCSD) to study the field of glycobiology in Dr. Esko’s lab and to help start Zacharon. Dr. Glass and Dr. Esko founded Zacharon to take advantage of novel technology developed in Dr. Esko’s lab and this untapped source of new drugs.

Dr. Glass received his Ph.D. from the University of California, Berkeley. His graduate and postgraduate research with Dr. Elaine Fuchs at the University of Chicago, Chicago, IL and The Scripps Research Institute in La Jolla.

Tim Scott is co-founder and President of Pharmatek, a formulation company in San Diego. He is also a co-founder of Diakron Pharmaceuticals, a pharmaceutical company focused on cardiovascular disease. He is a member of the Tech Coast Angels, providing due diligence and drug development expertise for TCA’s BioMedTrak screening group. Mr. Scott serves on the Board of Directors for Orphagen Pharmaceuticals, an orphan nuclear receptor discovery company. He also serves as vice president of the Board of Trustees for The Children School, an independent school located in La Jolla, California. He earned his B.A. in Biochemistry from the University of California, San Diego. He earned his J.D. from the University of San Diego and is a member of the California Bar.

Dr. Thornton is recognized as an expert in pharmaceutical development and sits on the Board of Directors of the Infectious Disease Science Center of the Torrey Pines Institute for Molecular Studies (La Jolla). In his present position at Pain Therapeutics and formerly as V.P of Research and Development at Apovia Pharmaceuticals, Dr. Thornton has been managing clinical trials worldwide for over 7 years. Apovia Pharmaceuticals was an international vaccine company formed when EVAX Technologies AG acquired Immune Complex Corporation (San Diego, CA). Dr. Thornton served as President of Immune Complex Corporation, a company formed to commercialize advances in vaccine technology. Prior to Immune Complex Corporation, he served as Vice President of R&D for GeneMedicine, Inc, in Woodlands, Texas. Prior to that, Dr. Thornton was Director of Pharmaceutical Research at RW Johnson (a Johnson & Johnson company) in San Diego and Australia for 15 years. Dr. Thornton received his Ph.D. from the University of Texas Health Science Center in Houston, Texas.